Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. exclusions exist for orphan drug designation and biosimilar competition ).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

FEBRUARY 1, 2024

Confidence Amidst Funding Challenges The resilience and confidence observed amidst funding challenges within the biotech sector represent a testament to the industry’s steadfast commitment to innovation and transformative advancements in healthcare.

Recruitment 52

Recruitment Healthcare Healthcare Management 52

Clarivate

AUGUST 27, 2024

FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up. Abbott’s Volt should join the party in early 2026. Still, analysts and providers project that Farapulse, which has more than 70% of the global market today, will continue to dominate at least through 2025.

Marketing 52

Marketing Competition FDA Electronics 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. That impacts launches most. Lastly, the growing economic crisis creates increasing challenge for medicines funding. appeared first on.

Doctors 59

Doctors Medicine Marketing Sales 59

European Pharmaceutical Review

FEBRUARY 7, 2023

However, a delicate balance will need to be struck between the need for affordable and accessible medicinal products and the desire to foster innovation and competitiveness in the EU. Edward Turtle is a products lawyer, regulatory advisor and litigator with particular experience in the healthcare, technology and consumer product sectors.

Medical 117

Medical Government Marketing Medicine 117

Evolve Your Success

JANUARY 24, 2023

If you’re someone that’s trying to get into medical sales, maybe it’s pharmaceutical, medical device, or any kind of healthcare sales, then you better be tuning in to this episode. They’re healthcare sales reps. If it’s 2026 and you’re reading this, this happened in 2023.

Medical sales 52

Medical sales Sales Medical Education 52

PM360

SEPTEMBER 28, 2022

healthcare system with major implications for the Medicare Advantage and Medicare Part D programs. Maximum Fair Prices published: The first round of negotiated Maximum Fair Prices will be published in August 2024, scheduled to take effect in 2026. On August 16, 2022, President Biden signed the Inflation Reduction Act (IRA) into law.

Government 97

Government Manufacturing Prescription Marketing 97

Clarify Health

FEBRUARY 6, 2024

That way, they can continue to grow membership and thrive against the competition. In 2026, payers will need to send prior authorization decisions within 72 hours for urgent requests and seven business days for standard requests. These changes are designed to make care easier to access for enrollees.

Networking 52

Networking Insurance Government Management 52

Clarivate

AUGUST 20, 2024

Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Clarivate

OCTOBER 17, 2024

Healthcare delivery has not been the hottest topic on the campaign trail this election season, despite sharp policy differences between the candidates and parties. These prior actions align with the Biden Administration’s policy of strict antitrust enforcement, particularly concerning healthcare. During the Sept.

Healthcare 52

Healthcare Healthcare Government Insurance 52